Xenon製藥 XENE 深 滬
已收盤 02-06 16:00:00 美东时间
41.38
+0.990
+2.45%
華盛通- 最 高41.745
- 今 開41.09
- 成交量 61.14万股
- 最 低 40.795
- 昨 收 40.39
- 總市值 31.98亿
- 52周最高 46.60
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 26.74
- 委 比 -47.69%
- 總股本 7727.50万
- 歷史最高 50.99
- 量 比 0.90
- 振 幅 2.35%
- 歷史最低 2.10
- 每 手 1
- 風險率 4.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Vancouver-based biopharmaceutical company Xenon Pharmaceuticals Inc. announced the grant of 42,300 stock options to ten new employees, approved by the Board's Compensation Committee with an effective date of Jan. 15, 2026. The options have an exercise price of $40.74 per share, vesting over four years, with 25% vesting after one year and the remainder vesting monthly. The stock options, granted under Nasdaq Listing Rule 5635(c)(4) as inducemen...
01-16 21:05
Xenon to Showcase Neuroscience Pipeline at J.P. Morgan Healthcare Conference
Xenon ( ($XENE) ) has provided an announcement. Xenon Pharmaceuticals Inc. anno...
01-05 22:19
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals (NASDAQ: XENE) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12, 2026. The presentation by President and CEO Ian Mortimer will take place from 9:00-9:40am Pacific Time (12:00-12:40pm Eastern Time). A live audio webcast and replay will be available on Xenon's Investors website. Xenon, a neuroscience-focused biopharmaceutical company, is advancing azetukalner, a Kv7 potassium cha...
01-05 13:30
All J.P. Morgan's top stock picks for 2026
J.P. Morgan identifies specific traits that define their Best Ideas for 2026. These companies typically possess: Strong Financial Health: Robust balance sheets and strong free cash flow generation. Pr...
01-01 01:44
Biohaven Misses The Mark In Depression Trial, Stock Falls
Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depressive symptoms in comparison to placebo.
2025-12-26 21:20
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $48
Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $44 to $48.
2025-12-12 01:12
期权扫描 | 获准对华出售H200芯片！英伟达一末日Call单大涨超66%；CoreWeave获看涨至150美元
获准对华出售H200芯片！英伟达一末日Call单大涨超66%；华纳兄弟探索看涨期权占逾7成；CoreWeave获看涨至150美元，较现价涨近74%>>
2025-12-09 12:02
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">Xenon Pharmaceuticals Inc. has granted equity inducement stock options totaling 39,250 shares to five new non-officer employees. The options, priced at $44.61 per share, vest over four years with monthly vesting after the first year. Xenon, a biopharmaceutical company focused on neuroscience, is advancing treatments for epilepsy, depression, and pain.</p>
2025-12-04 22:20
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
Vancouver-based Xenon Pharmaceuticals announced it will host an investor webinar on December 10, 2025, at 10:00-11:00 AM ET, focusing on azetukalner data from AES 2025. The webinar will cover new long-term data from the X-TOLE study on focal onset seizures, real-world data on epilepsy-related depression and titration burden, and commercialization updates for azetukalner. Registration is available via the provided link, and questions can be submit...
2025-12-03 13:30
